Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform

Abstract Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective of the tumor microenvironment to mouse studies that are better models but prohibitively expensive at scale. Chorioallantoic membrane (CAM) assays utilizing Japanese quail (Coturnix j...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Samuel V. Rasmussen, Noah E. Berlow, Lisa Hudson Price, Atiya Mansoor, Stefano Cairo, Sandra Rugonyi, Charles Keller
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/01643ff53c1b43ab8f9b56e7125517f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01643ff53c1b43ab8f9b56e7125517f1
record_format	dspace
spelling	oai:doaj.org-article:01643ff53c1b43ab8f9b56e7125517f12021-12-05T12:13:32ZPreclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform10.1038/s41598-021-02509-32045-2322https://doaj.org/article/01643ff53c1b43ab8f9b56e7125517f12021-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02509-3https://doaj.org/toc/2045-2322Abstract Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective of the tumor microenvironment to mouse studies that are better models but prohibitively expensive at scale. Chorioallantoic membrane (CAM) assays utilizing Japanese quail (Coturnix japonica) are a cost-effective screening method to precede and minimize the scope of murine studies for anti-cancer efficacy and drug toxicity. To increase the throughput of CAM assays we have built and optimized an 11-day platform for processing up to 200 quail eggs per screening to evaluate drug efficacy and drug toxicity caused by a therapeutic. We demonstrate ex ovo concordance with murine in vivo studies, even when the in vitro and in vivo studies diverge, suggesting a role for this quail shell-free CAM xenograft assay in the validation of new anti-cancer agents.Samuel V. RasmussenNoah E. BerlowLisa Hudson PriceAtiya MansoorStefano CairoSandra RugonyiCharles KellerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Samuel V. Rasmussen Noah E. Berlow Lisa Hudson Price Atiya Mansoor Stefano Cairo Sandra Rugonyi Charles Keller Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform
description	Abstract Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective of the tumor microenvironment to mouse studies that are better models but prohibitively expensive at scale. Chorioallantoic membrane (CAM) assays utilizing Japanese quail (Coturnix japonica) are a cost-effective screening method to precede and minimize the scope of murine studies for anti-cancer efficacy and drug toxicity. To increase the throughput of CAM assays we have built and optimized an 11-day platform for processing up to 200 quail eggs per screening to evaluate drug efficacy and drug toxicity caused by a therapeutic. We demonstrate ex ovo concordance with murine in vivo studies, even when the in vitro and in vivo studies diverge, suggesting a role for this quail shell-free CAM xenograft assay in the validation of new anti-cancer agents.
format	article
author	Samuel V. Rasmussen Noah E. Berlow Lisa Hudson Price Atiya Mansoor Stefano Cairo Sandra Rugonyi Charles Keller
author_facet	Samuel V. Rasmussen Noah E. Berlow Lisa Hudson Price Atiya Mansoor Stefano Cairo Sandra Rugonyi Charles Keller
author_sort	Samuel V. Rasmussen
title	Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform
title_short	Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform
title_full	Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform
title_fullStr	Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform
title_full_unstemmed	Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform
title_sort	preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/01643ff53c1b43ab8f9b56e7125517f1
work_keys_str_mv	AT samuelvrasmussen preclinicaltherapeuticsexovoquaileggsasabiomimeticautomationreadyxenograftplatform AT noaheberlow preclinicaltherapeuticsexovoquaileggsasabiomimeticautomationreadyxenograftplatform AT lisahudsonprice preclinicaltherapeuticsexovoquaileggsasabiomimeticautomationreadyxenograftplatform AT atiyamansoor preclinicaltherapeuticsexovoquaileggsasabiomimeticautomationreadyxenograftplatform AT stefanocairo preclinicaltherapeuticsexovoquaileggsasabiomimeticautomationreadyxenograftplatform AT sandrarugonyi preclinicaltherapeuticsexovoquaileggsasabiomimeticautomationreadyxenograftplatform AT charleskeller preclinicaltherapeuticsexovoquaileggsasabiomimeticautomationreadyxenograftplatform
_version_	1718372113243439104

Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform

Ejemplares similares